Phase 2 MIRA primary analysis trial results (12-week) for

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking...

Related Keywords

Switzerland ,Dublin ,Ireland ,Berlin ,Germany ,Namrata Taak ,Patricia Sousa ,Ashley Tapp ,Mary Jane Elliott ,Matthias Bodenstedt ,Moonlake Immunotherapeutics ,Moonlake Nanobody ,Vincent University Hospital ,American College Of Rheumatology Conference ,European Academy Of Dermatology ,Nasdaq ,Charles Institute Of Dermatology ,International Hidradenitis Suppurativa Severity Score System ,Charles Department Of Dermatology ,Venereology Congress ,University College Dublin ,European Academy ,Charles Department ,University Hospital ,Charles Institute ,American College ,Rheumatology Conference ,Hidradenitis Suppurativa Clinical Response ,Dermatology Life Quality Index ,Numerical Rating Scale ,Global Assessment ,Skin Pain ,Global Assessment Score ,Psoriasis Area ,Severity Index ,Securities Litigation Reform Act ,Jane Elliott ,Nasdaq Mltx ,Moonlake Immunotherapeutics Ag ,Moonlake ,Hidradenitis Suppurative ,Adv ,